secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-148920
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics appoints Eric J. Daniels as CDO; base salary $460K, equity grant
--------------------------------------------------------------------------------

- Daniels becomes Chief Development Officer effective April 20, 2026, reporting to CEO.
- Prior role: Chief Development Officer at Kiora Pharmaceuticals (NASDAQ:KPRX) from Oct 2021 to Apr 2026.
- Initial annual base salary of $460,000; target bonus of 40% of base salary.
- Equity inducement: option for 20,000 shares vesting over 4 years (1-yr cliff) and 20,000 RSUs vesting over 3 years.
- Severance on involuntary termination: 12 months' salary plus target bonus, plus vesting acceleration on 9 months of unvested equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/0001193125-26-148920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/pstv-20260408.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-148920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer